☰ Chemistry Tree

Amarnath (Amar) Natarajan, Ph.D.

Affiliations:

2009-

Eppley Institute for Cancer Research

University of Nebraska Medical Center, Omaha, NE, United States

Area:

Medicinal Chemistry

Website:

https://www.unmc.edu/eppley/about/faculty/natarajan.html

Google:

"Amarnath Natarajan"

Mean distance: (not calculated yet)

Tree Publications Similar researchers PubMed Report error

Parents

José S. Madalengoitia	grad student	1996-2001	University of Vermont
(Molecular diversity approach to the synthesis of peptide derived metal complexes and their evaluation as oxidation catalyst and the synthesis of a novel conformationally constrained lysine analogue based on the 3-AZA-bicyclo[3.1]hexane system)

Children

Vashti C. Bryant	grad student	2006-2011	UTMB
Ziyan Y. Pessetto	grad student	2007-2011	University of Nebraska Medical Center
Eric A. Kumar	grad student	2008-2013	University of Nebraska Medical Center
Jamie L. Arnst	grad student	2010-2014	University of Nebraska Medical Center
Elizabeth C. Blowers	grad student	2011-2015	University of Nebraska Medical Center
Gregory F. Hollis	grad student	2014-2015	University of Nebraska Medical Center
Jacob I. Contreras	grad student	2012-2017	University of Nebraska Medical Center
Caroline M. Robb	grad student	2013-2017	University of Nebraska Medical Center
Margaret A. Taylor	grad student	2015-2017	University of Nebraska Medical Center
Smit Kour	grad student	2016-2020	University of Nebraska Medical Center
Hannah M. King	grad student	2017-2021	University of Nebraska Medical Center

Collaborators

Sandeep Rana	collaborator	2012-2019	University of Nebraska Medical Center
(Postdoctoral associate, Instructor, Research Asst. Professor)

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Yin L, Zeng Y, Zeng R, et al. (2021) Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. Oncogene
Rana S, Mallareddy JR, Singh S, et al. (2021) Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase. Cancers. 13
Robb CM, Kour S, Contreras JI, et al. (2020) Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463
Rana S, Kour S, Sonawane YA, et al. (2020) Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design
Tom EC, Mushtaq I, Mohapatra BC, et al. (2020) EHD1 and RUSC2 control basal EGFR cell surface expression and recycling. Molecular and Cellular Biology
Ahmed A, Boulton S, Shao H, et al. (2019) Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective. Cells. 8
Zheng XF, Acharya SS, Choe KN, et al. (2019) A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1. Nature Communications. 10: 4252
Kour S, Rana S, Contreras JI, et al. (2019) CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429
Rana S, Bendjennat M, Kour S, et al. (2019) Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters
Al-Mugotir M, Kolar C, Vance K, et al. (2019) A simple fluorescent assay for the discovery of protein-protein interaction inhibitors. Analytical Biochemistry

See more...